In POHs March Newsletter Harry Rosen wrote in his Corporate...

In POHs March Newsletter Harry Rosen wrote in his Corporate Update that POH was in discussions with parties on OTCs (deal ann 2 days later on JV with Quigley Corp); Animal Health (deal ann on Insulin for Animals with Novartis last week) and Dermatological Drugs.

So I think it fair to say we can expect a deal on Derma drugs soon.

What is a Dermatological Drug? These are drugs to treat skin disorders and diseases. They generally fall into the folling categories:

Acne and Rosacea

Antiaging and Photodamage

Dermatitis and Seborrhea

Fungal Infections

Hair Loss and Hair Removal

Hyperpigmentation/Melasma

Psoriasis

Skin Cancer, and

Other Skin Disorders.

POH has done a substantial amount of research in this area as highlighted by its Phase 1b Clinical Trial in April 2009 on Retinoic Acid. In this trial ,one hour after application of POHs TPM retinoic acid formulation, Phosphagenics delivered, on average, 375% more retinoic acid into the skin than the commercial product, Retin-A. This trial showed that the POH formulation achieved greater efficacy, no erythmea, and elimination of the risk of systemic toxicity due to the targeted, localised delivery of the active into the skin and muscle tissues while avoiding systemic exposure.

So what do we think

KC